Over three decades, LINK has developed excellence in manufacturing a large portfolio of reagents for oligonucleotide synthesis, which are sold across the world. As a result, our products are found in many research, diagnostic and increasingly therapeutic oligonucleotides. In 2017, LINK was acquired by LGC, a leading international tools and solutions provider for the life sciences industry, Following the acquisition, LGC is combining its Biosearch oligonucleotide reagent group, its Prime Synthesis CPG business and LINK into a newly-formed Nucleic Acid Chemistry (NAC) business unit that will sit within its Genomics division. Of this exciting development, Brian Kim, President and Managing Director, Genomics division, LGC, said, “We are delighted to be adding LINK to our portfolio of oligonucleotide reagents. LINK’s products are a great complement to LGC’s, providing our customers with an expanded product range, increased supply chain security, improved global logistics and industry-leading customer support.” To learn more about what we can offer you, please visit www.linktech.co.uk.